Oxford Immunotec Applauds Updated Guidelines from the American Academy of Pediatrics Supporting Expanded Use of the T-SPOT®.TB Test

Oxford Immunotec Applauds Updated Guidelines from the American Academy of Pediatrics Supporting Expanded Use of the T-SPOT^®.TB Test

OXFORD, United Kingdom and MARLBOROUGH, Mass., June 5, 2018 (GLOBE NEWSWIRE) — Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it applauds updated guidelines from the American Academy of Pediatrics (AAP) on screening for latent tuberculosis infection (LTBI).

The AAP guidelines include specific recommendations for the use of interferon gamma release assays (IGRAs), such as Oxford Immunotec’s T-SPOT.TB test. The recommended age for IGRA use has been lowered from five years to two years in the updated guidelines, which were published in the AAP’s 2018 Red Book: Report of the Committee on Infectious Diseases (COID). The Red Book contains a composite summary of current recommendations representing the policy of the AAP on various aspects of infectious diseases and is issued every three years.

“These updated recommendations closely follow the recent publication¹ of a multi-year study demonstrating the strong performance of our T-SPOT.TB test in children, including those below the age of five,” said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. “We are delighted to see expanded support for the use of our test in this important patient population.”

¹ Mandalakas AM, Highsmith HY, Harris NM, et al. T-SPOT.TB Performance in Routine Pediatric Practice in a Low TB Burden Setting. Pediatr Infect Dis J. 2018;37(4):292-297. This study included pediatric samples received at Oxford Diagnostic Laboratories between 2010 and 2015. The authors concluded that the T-SPOT.TB test provides evaluable results in 98% of children, including HIV-infected and young children. In nearly 44,000 tests, the invalid rate of T-SPOT.TB was determined to be less than 1% for children older than 12 months and 1.8% for children younger than one year.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company’s first product is the T-SPOT.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company’s second product line is a range of assays for tick-borne diseases, such as Lyme disease. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.

Forward-Looking Statements

This release contains forward-looking statements that involve risks and uncertainties, including statements about our anticipated plans, objectives, and intentions, including effects on future financial and operating results, prospects for sales of our products and other statements that are not historical facts. The forward-looking statements in this release are based on current expectations, assumptions and data available as of the date of this release and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to: decisions by regulatory authorities, hospitals and other health care institutions, laboratories, physicians, patients and third party payers that could affect the Company’s business and prospects; as well as our ability to expeditiously and successfully expand our sales and distribution networks. The risks included above are not exhaustive. Other factors that could adversely affect our business and prospects are described under the “Risk Factors” section in our filings with the Securities and Exchange Commission (“SEC”). Our filings are available for free by visiting the investor section of our website, www.oxfordimmunotec.com, or the SEC’s website, www.sec.gov.

Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. You should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. We do not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.

CONTACT:

For Media and Investor Inquiries:
Karen Koski
Head of Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377
kkoski@oxfordimmunotec.com